Search
Briacell Therapeutics Corp
BCTXAdd to Watchlist
3.470USD
+0.230+7.10%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
25.16MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+7.10%
5 Days
+14.52%
1 Month
+4.83%
6 Months
-51.20%
Year to Date
-51.20%
1 Year
-87.87%
Key Figures
3.270Open
3.500High
176.65KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
2.44%Turnover Ratio
3.240Prev. Close
3.260Low
450.43KTurnover
LossP/E Static
1.05P/B
0.00%Div Yield TTM
-139.50%ROA
49.00052wk High
1.57Volume Ratio
-26.31MNet Profit
7.25MShares
-14.4132EPS TTM
1.65Beta
-171.72%ROE
4.13052wk Low
7.41%Amplitude
--Gross Margin
25.16MMarket Cap
-0.14Reward/Risk
6.54%Risk Rate
TradingKey Stock Score of Briacell Therapeutics Corp
Currency: USD Updated: 2026-06-30Key Insights
Briacell Therapeutics Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 258 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 40.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Briacell Therapeutics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Briacell Therapeutics Corp Highlights
StrengthsRisks
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.22, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 155.47K shares, decreasing 29.34% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
40.000
Target Price
+199.85%
Upside Space
Briacell Therapeutics Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Briacell Therapeutics Corp Info
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Ticker SymbolBCTX
CompanyBriacell Therapeutics Corp
CEOWilliams (William V)
Websitehttps://briacell.com/
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
FAQs
What is the current price of Briacell Therapeutics Corp (BCTX)?
The current price of Briacell Therapeutics Corp (BCTX) is 3.47.
What is the symbol of Briacell Therapeutics Corp?
The ticker symbol of Briacell Therapeutics Corp is BCTX.
What is the 52-week high of Briacell Therapeutics Corp?
The 52-week high of Briacell Therapeutics Corp is 49.00.
What is the 52-week low of Briacell Therapeutics Corp?
The 52-week low of Briacell Therapeutics Corp is 4.13.
What is the market capitalization of Briacell Therapeutics Corp?
The market capitalization of Briacell Therapeutics Corp is 25.16M.
Is Briacell Therapeutics Corp (BCTX) currently rated as Buy, Hold, or Sell?
According to analysts, Briacell Therapeutics Corp (BCTX) has an overall rating of Buy, with a price target of 40.00.
What is the Earnings Per Share (EPS TTM) of Briacell Therapeutics Corp (BCTX)?
The Earnings Per Share (EPS TTM) of Briacell Therapeutics Corp (BCTX) is -62.19.